Search results
Showing 1726 to 1740 of 1809 results for nice guidelines
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.
Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the
Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
Discontinued [GID-TA10334]
Testing strategies for Lynch syndrome in people with endometrial cancer (DG42)
Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer
Discontinued [GID-TA10072]
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
Discontinued [GID-TA10310]
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development [GID-TA10555] Expected publication date: TBC
Evidence-based recommendations on aripiprazole for treating moderate to severe manic episodes in young people with bipolar I disorder.
Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.
Suburethral synthetic sling insertion for stress urinary incontinence in men (IPG256)
This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG97. NICE has no plans to carry out further assessment of this procedure under the Interventional procedures programme.
This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG97. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.
Multiple sclerosis: Management of multiple sclerosis in primary and secondary care (CG8)
This guidance has been updated and replaced by NICE guideline CG186.